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Key points
 This study reports a functional assessment of the subunit composition of inhibitory ionotropic
GABAA receptors (GABAARs) and glycine receptors (GlyRs) expressed by excitatory cortical
neurones derived from human embryonic stem cells (hECNs).
 GABAARs expressed by hECNs are predominantly composed of α2/3β3γ2 subunits; such a
composition is typical of that reported for GABAARs expressed in rodent embryonic cortex.
 Analysis of GlyRs expressed by hECNs indicates they are likely to contain α2 and β
subunits – a composition in rodents that is associated with a late embryonic/early postnatal
period of development.
Abstract We have assessed, using whole-cell patch-clamp recording and RNA-sequencing
(RNA-seq), the properties and composition of GABAA receptors (GABAARs) and
strychnine-sensitive glycine receptors (GlyRs) expressed by excitatory cortical neurons derived
fromhumanembryonic stemcells (hECNs).The agonistsGABAandmuscimol gaveEC50 valuesof
278μMand182μM, respectively, and thepresence of aGABAARpopulationdisplaying lowagonist
potencies is supported by strong RNA-seq signals for α2 and α3 subunits. GABAAR-mediated
currents, evoked by EC50 concentrations of GABA, were blocked by bicuculline and picrotoxin
with IC50 values of 2.7 and 5.1 μM, respectively. hECN GABAARs are predominantly γ
subunit-containing as assessed by the sensitivity of GABA-evoked currents to diazepam and
insensitivity to Zn2+, together with the weak direct agonist action of gaboxadol; RNA-seq
indicated a predominant expression of the γ2 subunit. Potentiation of GABA-evoked currents
by propofol and etomidate and the lack of inhibition of currents by salicylidine salycylhydrazide
(SCS) indicate expression of the β2 or β3 subunit, with RNA-seq analysis indicating strong
expression of β3 in hECN GABAARs. Taken together our data support the notion that hECN
GABAARs have an α2/3β3γ2 subunit composition – a composition that also predominates in
immature rodent cortex. GlyRs expressed by hECNs were activated by glycine with an EC50
of 167 μM. Glycine-evoked (500 μM) currents were blocked by strychnine (IC50 = 630 nM)
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and picrotoxin (IC50 = 197 μM), where the latter is suggestive of a population of heteromeric
receptors. RNA-seq indicates GlyRs are likely to be composed of α2 and β subunits.
(Received 17 June 2014; accepted after revision 6 August 2014; first published online 28 August 2014)
Corresponding author D. J. A. Wyllie: Centre for Integrative Physiology, University of Edinburgh, Hugh Robson
Building, George Square, Edinburgh EH8 9XD, UK. Email: dwyllie1@staffmail.ed.ac.uk
Abbreviations D-AP5, (2R)-amino-5-phosphonovaleric acid; CNQX, 6-cyano-7-nitroquinoxaline-2,3-dione; DIV,
days in vitro; GABAAR, γ-aminobutyric acid receptor type A; GFAP, glial fibrilary acidic protein; GlyR, glycine receptor;
hECN, human excitatory cortical neurone; hPSC, human pluripotent stem cell; PCR, polymerase chain reaction;
RNA-seq, RNA sequencing; VGLUT1, vesicular glutamate transporter 1.
Introduction
γ-Aminobutyric acid (GABA) type A receptors
(GABAARs) are the principal inhibitory neurotransmitter
receptors in the mammalian adult brain. GABAARs are
a pentameric ligand-gated anion channels that can be
potentially composed of 19 known subunits (α1–6, β1–3,
γ1–3, δ, ε, π, θ and ρ1–3), giving rise to a large number
of potential receptor stoichiometries (Olsen & Sieghart,
2009). Alongside GABAARs, strychnine-sensitive glycine
receptors (GlyRs) form another major class of pentameric
ligand-gated anion channel that can be potentially
composed of 5 subunits, α1–4 and β (Lynch, 2009).
GABAAR and GlyR subunits are each associated with a
highdegreeof spatial anddevelopmental regulationwithin
the CNS (Malosio et al. 1991; Laurie et al. 1992; Fritschy
et al. 1994; Flint et al. 1998). In this regard, GABAAR
composition is currently limited to approximately 30
known variants. Moreover, subunit identity typically
imparts various pharmacological specificities to the
GABAAR complex and, collectively, these properties make
GABAARs a key pharmacological target for a range of
neurological disorders (Olsen & Sieghart, 2009). The
increasing knowledge regarding the functions of GlyRs
within the developing CNS indicates that these receptors
too are likely to be relevant pharmacological targets (Avila
et al. 2013a).
The technological advance in the ability to generate
human excitatory cortical neurones (hECNs) from
pluripotent stem cells (hPSCs) gives the potential to study
human-specific physiology and disease in vitro. We have
previously reported a protocol that generates cultures of
predominantly hECNs by 4 weeks of differentiation from
anterior neural precursors derived from various stem cell
lines (Bilican et al. 2014). The translational impact of
this technology is ultimately determined by the ability
of hECNs to display properties that reflect neurones in
their native environment (Yang et al. 2011; Sandoe &
Eggan, 2013). Indeed, we have previously identified that
hECNs are a useful model to study the maturation of
AMPAR composition and the reduction in intracellular
Cl− concentration that is observed in native neuronal
development (Livesey et al. 2014). The present study
characterises the likely subunit composition of GABAAR
and GlyRs expressed by hECNs and illustrates that their
subunit composition are likely to be similar to those that
have been described for inhibitory ionotropic receptors
expressed in immature rodent cortex.
Methods
In vitro hECN preparation
A detailed description of the derivation of hECNs can
be found in Bilican et al. (2014). Briefly, hECNs were
differentiated from anterior neural precursors that were
derived from the H9 human embryonic stem cell line
(WiCell), which was obtained under ethical/IRB approval
of the University of Edinburgh. Experiments were carried
out on cells that had been differentiated and maintained
in culture for 28–42 days in vitro (DIV), or 49–56 DIV.
At these time points, around 70% of cells were neuronal
(β3-tubulin+), with little contamination from neural pre-
cursor cells (nestin+), astrocytes (GFAP+) or GABA-ergic
(GAD65/67+) interneurons (Bilican et al. 2014; Livesey et
al. 2014). Neurones were consistent with an excitatory
(VGLUT1+) identity that also exhibited properties of
neurones of the upper and lower layers of the cortex (see
Bilican et al. 2014; Livesey et al. 2014).
Electrophysiology
The whole-cell patch-clamp configuration was used to
record currents from hECNs using an Axon Multiclamp
700B amplifier (Molecular Devices, Sunnyvale, CA,
USA). Patch electrodes (4–7 M
) were filled with
an ‘internal’ recording solution comprising (in mM):
potassium gluconate 155, MgCl2 2, Na-HEPES 10,
Na-PiCreatine 10, Mg2-ATP 2 and Na3-GTP 0.3, pH 7.3
(300 mOsmol l–1). Coverslips containing hECNs were
placed in the recording chamber, which was superfused
with an ‘external’ recording solution composed of (inmM)
NaCl 152, KCl 2.8, HEPES 10, CaCl2 2, glucose 10, pH 7.3
(320–330mOsmol l–1) using a gravity-feed systemat room
temperature (20–23°C) with a flow rate of approximately
C© 2014 The Authors. The Journal of Physiology C© 2014 The Physiological Society
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4mlmin−1. Time for complete bath solution exchangewas
approximately 5 s, but agonist onset times were dependent
on position of perfusion line and cell; the rise-time of
agonist-evoked whole-cell currents was < 2 s and all
responses were measured at steady state. We observed that
faster solution exchange rates were frequently associated
with hECNs detaching from coverslips. The ‘external’
recording solutionwas supplementedwith CNQX (5μM),
D-AP5 (50μM), TTX (300 nM), and in the case ofGABAAR
experiments, strychnine (20 μM). Recordings were made
at aholdingpotential of 0mV(−14mVwhencorrected for
the liquid junction potential), which gave a large driving
force (80 mV), resulting in inward flux of Cl− ions.
Series resistances (Rs) were between 10 and 30 M
 and
compensated between 50 and 80%. Experiments were
terminated if series resistance shifted more than 20%.
Before each experiment, three bath applications of
a given concentration of agonist that gave equivalent
current amplitudes within 15% of the initial amplitude
were obtained to establish a stable response. Similarly, a
response to a control concentration of agonist was applied
at the end of the recording to ensure stability. Data were
only taken if the amplitude of the final control response
was within 15% of the initial controls. Selective agonists,
antagonists and allosteric modulators were purchased
either from Tocris Bioscience (Bristol, UK) or Abcam
(Cambridge, UK).
RNA-sequencing
For RNA-seq, RNA was isolated from four biological
replicates using the RocheHPRNA Isolation kit according
to manufacturer’s instructions. Total RNA was assessed
for quality (Agilent Bionalyzer) and quantity (Invitrogen
Qubit) before library preparation. Illumina libraries were
prepared from 1 μg of total RNA using TruSeq RNA
Sample Prep Kit v2 with a 10 cycle enrichment step as
per the manufacturer’s recommendations. Final libraries
were pooled in equimolar proportions before Illumina
sequencing on a HiSeq 2500 platform using 100 base
paired-end reads in rapidmode. Raw reads were processed
using RTA 1.17.21.3 and Casava 1.8.2 (Illumina). Reads
were mapped to the primary assembly of the human
reference genome contained in Ensembl release 75. A
genome index was built with Bowtie, version 1.0.0; default
options; (Langmead et al. 2009), and then reads mapped
with TopHat, version 2.0.10, (Kim et al. 2013); for
TopHat, coverage-based search for junctions was disabled,
otherwise default values were used for all options. Gene
expression was then estimated with Cufflinks, version
2.2.0, (Trapnell et al. 2010; Roberts et al. 2011) using
gene annotations from Ensembl release 75. Cufflinks was
run in expression estimation mode only (-G flag), and
corrections for multi-read mapping (-u flag) and bias
(-b flag) were enabled; otherwise default values were
used for all options. Estimates of GABAAR and GlyR
subunit mRNA expression were then extracted in units
of fragments per kilobase of exon per million mapped
fragments, and normalised as expression relative to that
of the highest expressed subunit.
Data analysis
Recordings were low-pass filtered at 2 kHz, digitised
at 10 kHz via a BNC-2090A (National Instruments,
TX, USA) interface, and recorded to computer using
the WinEDR V2.7.6 Electrophysiology Data Recorder (J.
Dempster, University of Strathclyde, UK, http://spider.
science.strath.ac.uk/sipbs/software_ses.htm)
Agonist concentration–response curves were fitted
individually for each cell using the Hill equation:
I = Imax/(1 + (EC50/[A])nH),
where I is the current response to agonist concentration
[A], nH is theHill coefficient, Imax is themaximum current
and EC50 is the concentration of agonist that produces a
half-maximal response. Each data point was normalised to
the fitted maximum of the concentration–response curve,
then pooled, averaged and re-fitted again with the same
equation,with themaximumandminimumfor eachcurve
being constrained to asymptote to 1 and 0, respectively
(Frizelle et al. 2006; Wrighton et al. 2008).
Concentrations of antagonists required to inhibit
agonist-evoked responses by 50% (IC50) were determined
by fitting inhibition curves with the equation:
I = I [B]0/(1 + ([B]/IC50)nH),
where nH is the Hill coefficient, I[B]0 is the predicted
current in the absence of antagonist and [B] is the
concentration of the antagonist. Data points were again
normalised to the fitted maximum, before pooling,
averaging and re-fitting as described above.
Data are presented as mean ± standard error of the
mean (SEM). The number of experimental replicates
(cells) is denoted as ‘n,’ while ‘N’ represents number of de
novo preparations of batches from which ‘n’ is obtained.
Statistical analysis was conducted as described in the text
with the significance levels indicated as: P < 0.05 (∗),
P < 0.01 (∗∗) and P < 0.001 (∗∗∗).
Results
GABAA receptor characterisation
The potency of GABAAR agonists varies considerably
between GABAAR isoforms (Mortensen et al. 2011;
Karim et al. 2013). Thus, to characterise initially
the functional properties of GABAARs expressed by
C© 2014 The Authors. The Journal of Physiology C© 2014 The Physiological Society
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hECNs (28–42 DIV) differentiated from anterior neural
precursors derived from H9 human embryonic stem
cells (Bilican et al. 2014; see Methods) we conducted
concentration–response experiments using GABA and
the GABAAR-selective agonist muscimol. We pre-
viously established that hECNs robustly respond to
GABA at this time point (Livesey et al. 2014). After
establishing stable control responses to bath applications
of GABA (100 μM), or muscimol (300 μM), increasing
concentrations of agonist were applied sequentially to
generate concentration–response curves (Fig. 1A). Mean
EC50 values for GABA- and muscimol-activated currents
were found to be 278 ± 11 μM (n = 12, N = 2) and
182 ± 10 μM (n = 6, N = 2), respectively (Fig. 1B).
GABA (EC50)-evoked current responses were blocked by
GABAAR antagonists bicuculline and picrotoxin (Fig. 1C)
in a concentration-dependent manner (Fig. 1D) giving
respective IC50 values of 2.7 ± 0.2 μM (n = 5, N = 2) and
5.1 ± 0.2 μM (n = 4, N = 2).
We next performed a series of pharmacological
assays to assess the presence of γ and/or δ
subunit-containing GABAARs. Applications of γ-selective
allosteric potentiator diazepam(30nMand3μM) toGABA
(EC10; 35 μM)-mediated currents potentiated the control
GABA response by 10 ± 6 % (P = 0.1 vs. control) and
46 ± 10 % (P < 0.001 vs. control, Welch’s t test, n = 17,
N = 3), respectively, indicating the presence of the γ sub-
unit (Fig. 2A). In contrast, applicationsofZn2+ (10μMand
300μM),which selectively inhibitsGABAARs composedof
α andβ subunits only (Draguhn et al.1990), didnot inhibit
Figure 1. Agonist and antagonist pharmacology of hECN GABAARs
A, representative whole-cell current recordings of GABA and muscimol concentration–response experiments.
Currents were elicited by increasing concentrations of bath applications of GABA and muscimol (3 μM to
3 mM) after establishing 3 control GABA-evoked currents as indicated. Calibration bars 250 pA, 100 s. B, mean
agonist concentration–response curves for GABA and muscimol. Mean GABA data: EC50 = 278 ± 11 μM,
nH = 1.05 ± 0.02, n = 12, N = 2. Mean muscimol data: EC50 = 182 ± 10 μM; nH = 0.99 ± 0.02; n = 6, N = 2. C,
example currents illustrating the inhibition of GABA-evoked responses by increasing concentrations of picrotoxin
(upper panel) and bicuculline (lower panel). Calibration bars 250 pA, 100 s. D, mean inhibition curves for picrotoxin
and bicuculline antagonism of GABA (EC50) evoked currents. Mean bicuculline data: IC50 = 2.7 ± 0.2 μM;
nH = 0.98 ± 0.03; n = 5, N = 2. Mean picrotoxin data: EC50 = 5.1 ± 0.2 μM; nH = 1.22 ± 0.03; n = 4, N = 2.
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GABA (EC50)-evoked currents (10μM, 6± 3%, P= 0.053
vs. control; 300 μM, 11 ± 5 %, P = 0.052 vs. control;
unpaired t tests; n = 9, N = 1; Fig. 2B). Furthermore, the
potent δ-containing GABAAR-selective agonist gaboxadol
(3 μM and 300 μM; Storustovu & Ebert, 2006) gave
only nominal currents (6.0 ± 2.3% and 14.6 ± 3.7%;
both data P < 0.001 vs. GABA (3 mM); unpaired t tests;
n = 6–7, N = 1, respectively) compared to the maximum
response that could be elicited by GABA (3 mM; Fig. 2C),
confirming that a population of GABAARs that contain δ
subunits is negligibly expressed.Weconfirmed that the low
potency of GABA we observed was not a consequence of
the specific culture conditions that we employed. Indeed
GABApotencywas not influenced by the culture of hECNs
in atmospheric O2 48 h prior to recording (222 ± 13 μM,
n = 3, N = 1), the absence of brain-derived neuro-
trophic factor and glial cell-derived neurotrophic factor
media supplements (222 ± 36 μM, n = 5, N = 2), or
maintaining hECNs for extended (49–56 DIV) culture
periods (204 ± 17 μM, n = 5, N = 2). Moreover,
even for hECNs maintained for extended culture periods
gaboxadol (300 μM)-evoked currents remained very low
(9.7± 4.1 %, n= 4,N= 1) with respect to GABA-evoked
currents and indicated that hECNs maintained in culture
for prolonged time periods (49–56 DIV) did not begin to
express a δ-containing receptor population.
The presence of β subunits in hECN GABAARs
was confirmed by the potentiation by the intra-
venous anaesthetic propofol (10 μM) of GABA (EC30;
120 μM)-evoked currents which resulted in robust
potentiation of the control current responses by 144
% ± 29 % (Fig. 3A and B; P = 0.002 vs. control, unpaired
t test, n = 8, N = 2; Sanna et al. 1995; Hill-Venning
et al. 1997). Furthermore, direct activation of GABAARs
was observed when propofol (100 μM) was applied on its
own (98± 21 % relative to GABA (EC30; 120μM)-evoked
control; n = 7, N = 2; Fig. 3A and C). The intra-
venous anaesthetic etomidate (3 μM), which is selective
for β2/3 subunit-containing GABAARs (Hill-Venning et
al. 1997), also potentiated GABA (EC30; 120 μM)-evoked
currents by 75 ± 20 % (Fig. 3A and B; P = 0.01 vs.
control, unpaired t test, n = 6, N = 1) while application
on its own and at a higher concentration (300 μM)
directly activated GABAARs (116 ± 23 % relative to
GABA (EC30; 120 μM)-evoked control; n = 6, N = 1).
Taken together, these data suggest the presence of a large
complement of β2/3-containing GABAARs. The absence
of β1-containing GABAARs was indicated by the fact that
Figure 2. Modulation of hECN GABAARs
by diazepam, Zn2+ and gaboxadol
A, left panel: representative whole-cell
recording depicting the co-application of
diazepam (30 nM and 3 μM, as indicated by
bars) to control GABA-evoked responses. A,
right panel: modulation of
GABAAR-mediated currents by diazepam
(30 nM and 3 μM, n = 17, N = 3). Data are
presented as mean percentage modulation
with respect to control recordings. No
difference was observed between
percentage modulation and the batch from
which cells were prepared. Calibration bar
50 pA, 50 s. B, left panel: example
whole-cell recording depicting the
co-application of Zn2+ (10 μM and 300 μM,
as indicated by bars) to control
GABA-evoked responses. B, right panel:
mean percentage modulation of control
GABAAR-mediated currents by Zn2+ (n = 9,
N = 1). Calibration bar 100 pA, 50 s. C, left
panel: example whole-cell recording of
GABA (3 mM)-evoked currents and
gaboxadol (3 μM and 300 μM)-induced
currents. C, right panel: mean percentage
gaboxadol-induced activation of GABAAR
currents with respect to (w.r.t.) maximum
GABA-evoked currents (n = 6–7, N = 1).
Calibration bar 500 pA, 50 s.
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the selective inhibitor of β1-containing GABAARs, SCS
(Thompson et al. 2004), failed to antagonise GABA (EC30;
120 μM)-evoked currents (Fig. 3A and B; SCS vs. control,
P = 0.27 vs. control, unpaired t test, n = 8, N = 2).
As illustrated above GABA-evoked currents are
potentiated by diazepam which suggests that α4 and α6
subunits are absent from the GABAAR population in
hECNs since typically benzodiazepines are active at α1,
α2, α3, or α5-containing GABAARs (Olsen & Sieghart,
2009). To rule out the possibility of the expression of
α4 and α6 subunits, GABA (EC30; 120 μM)-elicited
currents were shown to be insensitive to the α4/α6 sub-
unit containing GABAAR inhibitor furosemide (100 μM;
P = 0.43 vs. control, unpaired t test, n = 6, N = 2;
Fig. 3D and E; Knoflach et al. 1996; Wafford et al. 1996).
Furthermore, the observed low GABA and muscimol
Figure 3. Modulation of hECN GABAARs by intravenous anesthetics, SCS, furosemide and zolipidem
A, upper panel: example trace showing potentiation of GABA-mediated whole-cell currents and direct activation
of GABAARs by propofol. A, middle panel: example trace showing potentiation of GABA-mediated whole-cell
currents and direct activation of GABAARs by etomidate. A, lower panel: example trace showing lack of inhibition
of GABA-mediated whole-cell currents by SCS. Calibration bars: 100 pA, 50 s (upper); 100 pA, 50 s (middle);
250 pA, 50 s (lower). B, mean percentagemodulation GABA-induced currents by the allosteric modulators propofol
(10 μM; n = 8, N = 2), etomidate (3 μM; n = 6, N = 1) and SCS (1 μM; n = 8, N = 2). C, mean percentage
direct activation propofol and etomidate expressed with respect to control responses to GABA. D, upper panel:
example trace showing lack of inhibition of GABA-mediated whole-cell currents by furosemide. D, lower panel:
example trace showing potentiation of GABA-mediated whole-cell currents by zolpidem (n = 6–8, N = 2 for
each condition). Calibration bars: 150 pA, 50 s (upper); 100 pA, 50 s (lower). E, mean percentage modulation
GABA-induced currents by the allosteric modulators furosemide (100 μM) and zolpidem (50 nM and 500 nM).
C© 2014 The Authors. The Journal of Physiology C© 2014 The Physiological Society
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potencies (Fig. 1B) argues against the expression of α4
and α6 subunits, and also α5 subunits, which typically
display high GABA potency (Mortensen et al. 2011; Karim
et al. 2013). To identify the nature of the α subunit we
examined the actions of zolpidem (50 nM and 500 nM),
which exhibits selectivity for α1-containing GABAARs
with lesser potency at α2- and α3-containing GABAARs
and negligible activity at α5-containing GABAARs (Sanna
et al. 2002). Co-application of zolpidem to GABA (EC10;
35 μM)-evoked currents resulted in only a mild
potentiation of control currents (Fig. 3D and E; 50 nM:
46± 10%; 500nM: 70± 10%,n= 8,N= 2), indicating the
majority of the GABAAR population expressed by hECNs
most likely contain α2 and/or α3 subunits.
To assess quantitatively the expression of GABAAR
subunits we examined the relative expression of sub-
unit mRNA transcripts via RNA-seq analysis (35 DIV).
Figure 4A shows the relative expression of α, β and γ
subunits with levels normalised to the highest expressed
subunit mRNA (β3). These data are consistent with
the pharmacological analysis of GABAARs expressed
by hECNs described above. For α subunits, we found
prominent mRNA expression of the α2 and α3 subunits
and very little detection of α4 and α6 subunits, whilst the
α1 and α5 subunit mRNAs were expressed to a moderate
extent. The β3 subunit is prominently expressed over
β1 and β2 subunits. Pharmacological data do not point
to the identity of the γ subunit(s) that are functionally
expressed by hECNs; however, the RNA-seq data indicate
the strongest expression of the γ2 subunit mRNA. In
agreement with the pharmacological analysis, levels of δ
subunitmRNA expressionwere considered to be nominal.
Strychnine-sensitive glycine receptor characterisation
GlyR characterisation was initially performed with
RNA-seq analysis of GlyR subunit mRNA transcripts in
hECNs (35 DIV; Fig. 4B). Both α2 and β subunits are
abundantly expressed at the mRNA level, whilst α1 and
α3 subunits are only nominally or weakly expressed,
respectively, relative to the α2 subunit. As expected, the
presence of α4 subunit mRNA was not detected given its
status as a pseudogene in humans (Lynch, 2009).
Functional expression of GlyRs was examined by
the ability of hECNs (7–35 DIV) to respond to bath
applications of glycine (500 μM). With increasing peri-
ods following differentiation the mean GlyR-mediated
current density profile displays amarked increase (Fig. 5A;
3.3 ± 2.2 pA pF–1 to 49.4 ± 8.4 pA pF–1; P < 0.001,
unpaired t test, n= 7,N= 2), indicating a strong temporal
up-regulation of functional GlyRs expressed by hECNs.
Furthermore by 28 DIV all cells examined gave currents
(Fig. 5A) and in all cases examined these were blocked by
the GlyR antagonist strychnine (20 μM).
The potency of glycine-evoked currents was assessed
by concentration–response experiments (Fig. 5B), from
which a curve-fitting of mean data yielded an
EC50 of 167 ± 20 μM (Fig. 5C). Glycine-evoked
(500 μM) currents were blocked fully by strychnine
in a concentration-dependent manner with an IC50 of
630 ± 59 nM (n = 5, N = 2; Fig. 5D and E). Note
that an increased agonist concentration, rather than the
typical EC50, was used to elicit suitable current responses
to measure antagonist effects. The composition of the
expressed GlyRs was probed using picrotoxin, which
exhibits selectivity for homomeric over heteromeric GlyR
forms, as the inclusion of the β subunit into the GlyR
results in a reduction in sensitivity to picrotoxin (Pribilla
et al. 1992; Wang et al. 2006; Lynch, 2009). Inhibition
of GlyRs by picrotoxin (Fig. 5D and E) gave an IC50 of
197 ± 22 μM (n = 5, N = 2), indicating the low potency
of this antagonist at hECN GlyRs and suggesting that
the majority of these receptors are heteromeric assembles
contain α and β subunits.
Figure 4. RNA-seq analysis of GABAAR and GlyR subunits
A, mean human GABAAR subunit mRNA estimated abundances
(N = 4) derived from RNA-seq analysis of hECNs (DIV 35). Data are
normalised to the largest mRNA signal (β3 subunit). The relative
expression of other GABAAR subunits (ε, π , θ and σ ) gave signals
that were considered to reflect the absence of mRNA for these
subunits. B, RNA-seq analysis human GlyR subunits as described in
A. Data are normalised as expression relative to α2 subunit mRNA
signal.
C© 2014 The Authors. The Journal of Physiology C© 2014 The Physiological Society
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Discussion
We have employed a variety of techniques to identify the
principal subunit composition of ionotropic GABAARs
and GlyRs expressed by hECNs. The identification of
GABAAR subunit regulation and expression is relevant
to neurodevelopment and neurological disease and thus
the ability of hPSC-derived neurones to express GABAARs
that reflect those seen in native neurones is essential if such
in vitro preparations are to be used for human-specific
development and disease modelling.
Our data establish that the predominant GABAAR
α subunits expressed by hECNs (DIV 28–45) are α2
and/or α3 subunits, which is consistent with an expression
profile predominantly exhibited by embryonic rodent
cortical neurones (Laurie et al. 1992; Fritschy et al. 1994).
Given that GABA-evoked currents were not inhibited
by furosemide, hECN GABAARs are considered to lack
α4 and α6 subunits. Furthermore, the mild modulatory
action of zolpidem suggests the absence of the α1 sub-
unit which is perhaps to be expected given that this
subunit is associated with a more mature neuronal
phenotype (Laurie et al. 1992; Fritschy et al. 1994). In
agreement with our pharmacological analysis, RNA-seq
also showed only moderate expression of α1 subunits
together with negligible expression of both α4 and α6
subunits compared to the relative abundance of trans-
cripts for both α2 and α3 subunits. We considered that
the functional expression of the α5 subunit, which is
associated with high agonist potency, was unlikely given
Figure 5. Agonist and antagonist pharmacology of hECN GlyRs
A, weekly percentage response to bath applications of glycine and the mean glycine-mediated current density.
n = 25–31, N = 3. B, representative whole-cell current recordings of glycine concentration–response experiments.
Currents were elicited by increasing concentrations of glycine after establishment of 3 control glycine-evoked
currents. Calibration bar 125 pA, 50 s. C, mean (± SEM) agonist concentration–response curve for glycine.
Mean glycine data: EC50 = 167 ± 20 μM; nH = 1.59 ± 0.1; n = 7, N = 2. D, upper panel: example current
recording of the inhibition of glycine-evoked (500 μM) responses by increasing concentrations of picrotoxin. D,
lower panel: strychnine inhibition of glycine-evoked (500 μM) currents amplitudes. Calibration bars 125 pA, 50 s.
E, mean inhibition curves for picrotoxin and strychnine antagonism of glycine-evoked currents. Mean picrotoxin
data: IC50 = 197 ± 22 μM; nH = 0.9 ± 0.06; n = 5, N = 2. Mean strychnine data: EC50 = 690 ± 59 nM;
nH = 1.17 ± 0.06; n = 5, N = 2.
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the relatively low levels of mRNA detected and the low
agonist potencies of GABA and muscimol. Indeed, low
potency is indicative of GABAARs that contain either α2
or α3 subunits (Mortensen et al. 2011; Karim et al. 2013).
High expression of the GABAAR β3 subunit has
been associated with rodent immature cortical neurones
(Laurie et al. 1992), though the β2 subunit is often also
reported to be substantially expressed in cortical neuro-
nes (Fritschy et al. 1994). Potentiation of GABA-evoked
currents by the low concentrations of intravenous
anaesthetics etomidate and propofol, direct activation by
high concentrations of etomidate and propofol, a lack of
SCS inhibition and a high level of mRNA expression for
the β3 subunit collectively demonstrate that hECNs are
likely to predominantly express β3 subunit-containing
GABAARs, although a contribution of β2 to GABAAR
stoichiometry cannot be ruled out.
The vast majority of GABAARs in the CNS are
γ2 subunit containing (Olsen & Sieghart, 2009).
RNA-seq data indicate that hECNs predominantly
express the γ2 subunit, in agreement with the
pharmacological findings that GABA-evoked currents
were potentiated by γ subunit-selective diazepam. Sub-
sets of δ subunit-containing GABAARs are selectively
expressed by certain cortical adult neuronal phenotypes
and importantly are commonly associated with
GABAAR-mediated tonic inhibition (Olsen & Sieghart,
2009). Nevertheless, our data indicate that hECNs lack δ
subunit-containing GABAARs as gaboxadol gave rise to
only low amplitude currents compared to those seen with
GABA. Furthermore, the finding that Zn2+ did not inhibit
GABA-evoked currents is consistent with the absence of
GABAARs containing only α/β subunits.
We have demonstrated that both RNA-seq analysis
and selective GABAAR pharmacology converge on a pre-
dominant GABAAR composition of α2/3β3γ2. Such iso-
forms are observed in recombinant expression systems to
have low agonist potency relative to other isoforms and
we similarly demonstrate that GABAAR expressed upon
hECNs exhibit relatively low agonist potency (Karim et
al. 2013). This GABAAR isoform is the most likely to be
widely expressed in the immature rodent cortex (Laurie
et al. 1992; Olsen & Sieghart, 2009). Nevertheless, our
data cannot rule out the presence of other GABAAR
isoforms expressed at a low level. However, inspection
of Brainspan (Atlas of the Developing Human Brain
http://www.brainspan.org/rnaseq/search) indicates that
the levels of mRNA we report from the RNA-seq analysis
of hECNs (35 DIV) are qualitatively similar to those seen
in human cortical neurones between 12 and 21 weeks post
conception. Thus, hECNs provide a system to investigate
the properties of human GABAAR pharmacology and
furthermore permit investigation of the role of GABAARs
in the maturing cortical neurones (Wang & Kriegstein,
2009).
In rodents, transient functional GlyR expression is a
key feature of early neocortical development (Flint et
al. 1998; Avila et al. 2013a). Indeed, hECNS maintained
for 28–42 DIV exhibited strong responses to glycine that
were blocked by the GlyR antagonist strychnine. Glycine
concentration–response experiments indicated glycine
potency was lower than previously reported recombinant
values (Pribilla et al. 1992) but is generally higher than
glycine potencies observed in native cortical preparations
(Flint et al. 1998; Okabe et al. 2004; Kilb et al. 2008; but
see Avila et al. 2013b). The reasons for these differences are
unknown, but may be related to systematic differences in
the solution exchange times of these studies, where slower
exchange times are more likely to give shallower observed
concentration–response curves. In this regard, the ability
to examine deactivation kinetics of GlyRs expressed by
hECNs in isolated patches using fast agonist application
may yield further details of GlyR identity (Mangin et al.
2003; Pitt et al. 2008; Krashia et al. 2011; Marabelli et al.
2013).
GlyRs expressed by rodent forebrain neurones have
been described as developing from an embryonic homo-
meric to postnatal heteromeric (β subunit-containing)
composition (Lynch, 2009). To investigate the functional
GlyR composition we used the antagonist picrotoxin,
which inhibits homomeric over heteromeric GlyRs
(Lynch, 2009). Given the observed low sensitivity of GlyRs
to picrotoxin, our results suggest that the principal GlyR
identity of hECNs is likely to a heteromeric α/β assembly.
Pharmacological tools to identify unambiguously the
nature of the α subunit within the heteromer are lacking
(but see Han et al. 2004); however, RNA-seq analysis
indicates that α2 subunit mRNA is the most abundantly
expressed. As is the case for GABAAR subunit expression,
levels of mRNA expression for GlyRs in our RNA-seq
analysis are consistent with a development age of around
12–21 weeks post conception (Atlas of the Developing
Human Brain http://www.brainspan.org/rnaseq/search).
Finally, it is of interest to note that there is trans-
ient expression of heteromeric α2/β GlyRs by rodent
Cajal–Retzius cells in early postnatal development (Okabe
et al. 2004). This class of neurone is considered to form
a significant population in our hECN cultures (Bilican
et al. 2014) and in this respect hECNsmay provide a useful
human model of GlyR development.
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